United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2003_register
executive
2010-09-23
article
Current Status of Useful Written Prescription Drug Information for Consumers: Public Meeting
Notices
D09002ee1bdebfaac
D09002ee1bdebfb33
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
Food and Drug Administration
originator
org
United States Government Agency or Subagency
The Food and Drug Administration (FDA) is announcing a public meeting to discuss the current status of the private sector's efforts to provide useful written prescription drug information to consumers. Public Law 104-180 adopted a goal that useful written information would be distributed to 75 percent of individuals receiving new prescriptions by the year 2000. An FDA-commissioned study of written information disseminated during 2001 with four widely-used prescription drugs reported the average ``usefulness'' of the information was only about 50 percent. The statute's goal for 2006 is that 95 percent of individuals receiving new prescriptions would receive useful written information. FDA is soliciting comments on and convening a public meeting to discuss what steps can be taken to improve the usefulness of such written prescription drug information in order to meet the year 2006 goal. FDA is posing four specific questions, and the agency is interested in responses to these questions and any other pertinent information stakeholders would like to share. Date and Time: The public meeting will be held on July 31, 2003, from 9 a.m. to 5 p.m. Registration to speak at the meeting must be received by June 30, 2003. Written or electronic comments will be accepted to the docket until September 2, 2003. Location: The public meeting will be held at the National Transportation Safety Board Boardroom and Conference Center, 429 L'Enfant Plaza, SW., Washington, DC 20594. (Phone: 202-314-6421; Metro: L'Enfant Plaza station on the green, yellow, blue, and orange lines). See: http://www.ntsb.gov/events/newlocation.htm. (FDA has verified the Web site address, but FDA is not responsible for any subsequent changes to the Web site after this document publishes in the Federal Register.) For Information Regarding This Notice Contact: Christine Bechtel, Center for Drug Evaluation and Research (HFD-006), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5458, email bechtelc@cder.fda.gov. If you need special accommodations due to a disability, please inform the contact person. Registration and Requests for Oral Presentation: No registration is required if you only plan to attend the meeting. Seating will be on a first-come, first-served basis. If you wish to make an oral presentation during the open public comment period of the meeting, you must register to speak at the meeting by submitting your name, title, business affiliation, address, telephone number, fax number, and e-mail address and you must specify on your registration that you wish to make a presentation. You must also submit the following: (1) A written statement for each question addressed, (2) the names and addresses of all who plan to participate, and (3) the approximate time requested to make your presentation. Individuals who register to make an oral presentation will be notified of the scheduled time for their presentation prior to the meeting. Depending on the number of presentations, FDA may have to limit the time allotted for each presentation. All participants are encouraged to attend the entire day. Presenters must submit two hard copies of each presentation given. For Registration Information Contact: Christine Bechtel, Center for Drug Evaluation and Research (HFD-006), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5458, email bechtelc@cder.fda.gov. Electronic registration for this meeting is available at: http://www.accessdata.fda.gov/scripts/oc/dockets/ meetings/meetingdocket.cfm, or, registration requests and materials can be sent to Christine Bechtel.
68 FR 33724
https://www.govinfo.gov/app/details/FR-2003-06-05/03-14212
03-14212
fr05jn03-88
4160-01-S
Docket No. 03N-0168
https://www.govinfo.gov/app/details/FR-2003-06-05/03-14212
https://www.govinfo.gov/content/pkg/FR-2003-06-05/html/03-14212.htm
https://www.govinfo.gov/content/pkg/FR-2003-06-05/pdf/03-14212.pdf
4 p.
33724
33727
68 FR 33724
Current Status of Useful Written Prescription Drug Information for Consumers: Public Meeting; Federal Register Vol. 68, Issue
NOTICE
03-14212
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket No. 03N-0168
4160-01-S
03-14212
Notice of public meeting; request for comments.
The Food and Drug Administration (FDA) is announcing a public meeting to discuss the current status of the private sector's efforts to provide useful written prescription drug information to consumers. Public Law 104-180 adopted a goal that useful written information would be distributed to 75 percent of individuals receiving new prescriptions by the year 2000. An FDA-commissioned study of written information disseminated during 2001 with four widely-used prescription drugs reported the average ``usefulness'' of the information was only about 50 percent. The statute's goal for 2006 is that 95 percent of individuals receiving new prescriptions would receive useful written information. FDA is soliciting comments on and convening a public meeting to discuss what steps can be taken to improve the usefulness of such written prescription drug information in order to meet the year 2006 goal. FDA is posing four specific questions, and the agency is interested in responses to these questions and any other pertinent information stakeholders would like to share. Date and Time: The public meeting will be held on July 31, 2003, from 9 a.m. to 5 p.m. Registration to speak at the meeting must be received by June 30, 2003. Written or electronic comments will be accepted to the docket until September 2, 2003. Location: The public meeting will be held at the National Transportation Safety Board Boardroom and Conference Center, 429 L'Enfant Plaza, SW., Washington, DC 20594. (Phone: 202-314-6421; Metro: L'Enfant Plaza station on the green, yellow, blue, and orange lines). See: http://www.ntsb.gov/events/newlocation.htm. (FDA has verified the Web site address, but FDA is not responsible for any subsequent changes to the Web site after this document publishes in the Federal Register.) For Information Regarding This Notice Contact: Christine Bechtel, Center for Drug Evaluation and Research (HFD-006), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5458, email bechtelc@cder.fda.gov. If you need special accommodations due to a disability, please inform the contact person. Registration and Requests for Oral Presentation: No registration is required if you only plan to attend the meeting. Seating will be on a first-come, first-served basis. If you wish to make an oral presentation during the open public comment period of the meeting, you must register to speak at the meeting by submitting your name, title, business affiliation, address, telephone number, fax number, and e-mail address and you must specify on your registration that you wish to make a presentation. You must also submit the following: (1) A written statement for each question addressed, (2) the names and addresses of all who plan to participate, and (3) the approximate time requested to make your presentation. Individuals who register to make an oral presentation will be notified of the scheduled time for their presentation prior to the meeting. Depending on the number of presentations, FDA may have to limit the time allotted for each presentation. All participants are encouraged to attend the entire day. Presenters must submit two hard copies of each presentation given. For Registration Information Contact: Christine Bechtel, Center for Drug Evaluation and Research (HFD-006), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5458, email bechtelc@cder.fda.gov. Electronic registration for this meeting is available at: http://www.accessdata.fda.gov/scripts/oc/dockets/ meetings/meetingdocket.cfm, or, registration requests and materials can be sent to Christine Bechtel.
Meetings:
Medical Devices Advisory Committee
Useful written prescription drug information for consumers; private sector efforts,
bechtelc@cder.fda.gov
fdadockets@oc.fda.gov
http://www.accessdata.fda.gov/scripts/oc/dockets/edockethome.cfm
http://www.accessdata.fda.gov/scripts/oc/dockets/meetings/meetingdocket.cfm
http://www.fda.gov/cder/reports/prescriptioninfo/default.htm
http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3874T1.htm
http://www.fda.gov/ohrms/dockets/dockets/dockets.htm
http://www.keystone.org
http://www.ntsb.gov/events/newlocation.htm
Federal Register
Vol. 68, no. 108
Office of the Federal Register, National Archives and Records Administration
2003-06-05
continuing
daily
deposited
born digital
229 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2003-06-05
P0b002ee1809a8361
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr05jn03
https://www.govinfo.gov/app/details/FR-2003-06-05
https://www.govinfo.gov/content/pkg/FR-2003-06-05/pdf/FR-2003-06-05.pdf
https://www.govinfo.gov/content/pkg/FR-2003-06-05/xml/FR-2003-06-05.xml
fdlp
33611
33830
DGPO
2010-09-23
2023-05-04
FR-2003-06-05
machine generated
eng
FR
FR-2003-06-05
68
108